Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease-Reference-Cited by-同舟云学术

Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease

Published:2015-02 Issue:2 Volume:17 Page:224-232
ISSN:1388-9842
Container-title:European Journal of Heart Failure
language:en
Short-container-title:Eur J Heart Fail

Author:

Pitt Bertram¹,Anker Stefan D.²,Böhm Michael³,Gheorghiade Mihai⁴,Køber Lars⁵,Krum Henry⁶,Maggioni Aldo P.⁷,Ponikowski Piotr⁸,Voors Adriaan A.⁹,Zannad Faiez¹⁰,Nowack Christina¹¹,Kim So-Young¹¹,Pieper Alexander¹²,Kimmeskamp-Kirschbaum Nina¹³,Filippatos Gerasimos¹⁴

Affiliation:

1. University of Michigan Medical School; 1500 E Medical Center Drive, 3910 Tauman Ctr Ann Arbor MI 48109 0366 USA

2. Department of Innovative Clinical Trials; University Medical Centre Göttingen; Göttingen Germany

3. Universitätskliniken des Saarlandes; Klinik für Innere Medizin III Homburg Germany

4. Feinberg School of Medicine; Northwestern University; Chicago IL USA

5. Heart Centre, Rigshospitalet; University of Copenhagen; Denmark

6. Centre of Cardiovascular Research and Education in Therapeutics; Monash University; Melbourne Australia

7. Research Centre of the Italian Association of Hospital Cardiologists; Florence Italy

8. Medical University; Clinical Military Hospital; Wrocław Poland

9. University Medical Centre Groningen; Groningen Netherlands

10. CHU Department of Cardiology; Université de Lorraine; Nancy France

11. Global Clinical Development; Bayer HealthCare AG; Leverkusen Germany

12. M.A.R.C.O. GmbH & Co. KG; Düsseldorf Germany

13. Global Research & Development Statistics; Bayer HealthCare AG; Leverkusen Germany

14. Department of Cardiology; Attikon University Hospital; Athens Greece

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Reference41 articles.

1. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators;Pitt;N Engl J Med,1999

2. Eplerenone in patients with systolic heart failure and mild symptoms;Zannad;N Engl J Med,2011

3. Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee;Butler;J Card Fail,2012

4. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC;McMurray;Eur J Heart Fail,2012

5. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines;Yancy;Circulation,2013

Cited by 79 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The significance of finerenone as a novel therapeutic option in diabetic kidney disease: a scoping review with emphasis on cardiorenal outcomes of the finerenone phase 3 trials;Frontiers in Medicine;2024-06-14

2. An Updated Review of the Management of Chronic Heart Failure in Patients with Chronic Kidney Disease;Reviews in Cardiovascular Medicine;2024-04-11

3. The role of a novel mineralocorticoid receptor antagonist, finerenone, in chronic kidney disease: mechanisms and clinical advances;Clinical and Experimental Nephrology;2023-10-17

4. Research Progress of Mineralocorticoid Receptor Antagonists on Diabetic Kidney Disease;Advances in Clinical Medicine;2023

5. Heart failure with reduced ejection fraction and the intersection of cardio-renal-metabolic medicine #CaReMe;European Heart Journal Supplements;2022-12-19